Vaccines and Public Health
Adult immunization rates are falling short of national targets. Learn how global, federal, and state policies affect vaccination uptake. Leverage our findings to guide your strategies. Rely on our expertise commercializing novel and therapeutic vaccines.
The State of COVID-19 Vaccine Candidate Development
The novel coronavirus (COVID-19) was first reported in Wuhan, China, on December 31, 2019, and within a month was declared a public health emergency of international concern (PHEIC) by the World Health Organization (WHO).
Medicare Spent $106B on Vaccine-Preventable Diseases Over 3 Years
Avalere analysis finds Medicare incurred $106.4 billion in 2016–2018 treating diseases potentially preventable with inline vaccines and select pipeline vaccine candidates. Those diseases also resulted in beneficiary costs of approximately $9.6 billion during the same time period.
Post-COVID-19 Considerations for the Commercial Health Coverage Market
Faced with a rapidly evolving healthcare environment, there are a number of important uncertainties that commercial insurers will need to consider when planning for the future
Opportunities to Modernize the Vaccine Injury Compensation Program
A proposal to eliminate shoulder injuries from the list of vaccine-related conditions that warrant federal compensation through the National Vaccine Injury Compensation Program (VICP) highlights the administrative challenges posed by these claims and provides an opportunity to consider reforms to modernize the program.
COVID-19 is Stressing a Fractured Mental Healthcare System in the US
Mental Health Awareness Month and the COVID-19 crisis intersect—and highlight challenges in the US mental health care system
Insights from the Influenza Vaccine Market for COVID-19 Vaccines
The evolution of the US influenza vaccine market offers insights into the potential barriers and opportunities for successful rollouts of novel COVID-19 vaccines.
COVID-19 and Its Impact on the Global Drug Supply Chain
Although COVID-19 is introducing new challenges within the global pharmaceutical supply chain, the current situation also creates opportunities for stakeholders to evaluate drug security and implement risk-mitigation strategies around shortages and required stockpiles.
The Impact of COVID-19 on the Health Insurance Industry
On April 9, Avalere experts came together to discuss the impact of COVID-19 on the health insurance industry.
Reducing Funding to WHO May Impact Existing Vaccines Programs
On April 15, President Trump announced his intention to halt funding to the World Health Organization (WHO), pending an investigation into WHO’s response to the COVID-19 pandemic. WHO first declared the outbreak a Public Health Emergency of International Concern on January 30 and a global pandemic on March 11. A reduction in funding from the US could limit WHO’s COVID-19 response activities as well as its regular vaccine programming, including product prequalification, global surveillance, and ongoing efforts to strengthen health systems.
Impact of the COVID-19 Pandemic on Sickle Cell Disease Management
Sickle cell disease (SCD) is a severe red blood cell disorder that disproportionately affects African-American and Hispanic populations. In the United States, there are approximately 100,000 individuals living with SCD (although there is a lack of accurate reporting and the exact number is unknown).
Diagnostic Testing and Patient Screening Are Key to Successful US COVID-19 Response
As the novel coronavirus (COVID-19) spreads throughout the United States, media and policy focus on the rollout of diagnostic testing for the disease has greatly increased. Understanding the role of testing and screening is key to the control of this outbreak.
Considerations for Patient Support Programs in the COVID-19 Era
As the economic and social impact of COVID-19 change how patients access and receive care, manufacturers and third-party suppliers must consider how to evolve their patient support programs to meet the shifting access and affordability needs of patients.
Interview: E7 – Get the Facts on COVID-19: Post-Acute Care
Tune into the seventh episode of our series that focuses on COVID-19. In episode 7, Avalere experts from the Health Plans and Provider’s practice discuss the short- and long-term implications for post-acute care as a result of COVID-19.
Patients Using DMARDs for Autoimmune Diseases May Encounter Access Challenges
As COVID-19 deaths increase, the FDA is evaluating and considering approval of treatments more quickly, but the rush to find treatment options is creating new access considerations for patients and providers.
Considerations for the Role of Pharmacies and the Retail Pharmacy Business Model in Response to COVID-19
As COVID-19 continues to stress the US healthcare system, pharmacists and retail pharmacies may help respond to the pandemic.
Amid COVID-19 Pandemic, Influenza Disease Burden Remains Significant
Although influenza disease burden is high, vaccine uptake remains low.
Medicare Part D Plans Continue to Require Cost Sharing for Vaccines
An Avalere analysis finds that Medicare Part D plans allow $0 cost-sharing for select vaccines just 4% of the time, likely affecting immunization uptake.
Home Testing Can Keep People Safe and Get Them Back to Work—Here’s How
On April 7, Gillian Woollett authored a Health Affairs blog piece with Ge Bai from the Johns Hopkins Carey Business School and Bruce Pyenson from Milliman about the role that testing plays in recovering from the COVID-19 pandemic.
COVID-19: Future Considerations for Biopharma
As the COVID-19 pandemic unfolds, stakeholders across the healthcare system are facing new realities that will affect the environment in which drugs are commercialized and accessed.
Where We Stand on COVID-19 Treatments
Globally, the need to flatten the epidemic curve of COVID-19 cases has become the top public health priority to save lives and minimize the burden on the health care system. In the absence of treatments and prophylactics for the novel coronavirus, social distancing and quarantine strategies continue to be implemented in the US.